MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào),，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù),。
CAS No. : 347174-05-4
MCE 國(guó)際站：Ferrostatin-1
產(chǎn)品活性：Ferrostatin-1 (Fer-1) 是一種有效的、選擇性的 ferroptosis 抑制劑,，抑制 Erastin 誘導(dǎo)的 HT-1080 細(xì)胞鐵死亡 (EC50=60 nM),。Ferrostatin-1 是一種人工合成的抗氧化劑，通過(guò)還原機(jī)制來(lái)防止膜脂的損傷,，從而抑制細(xì)胞死亡,。Ferrostatin-1 具有抗真菌活性,。
研究領(lǐng)域：Apoptosis | Anti-infection
作用靶點(diǎn)：Ferroptosis | Fungal
In Vitro: Ferrostatin-1 prevents erastin-induced accumulation of cytosolic and lipid ROS. Ferrostatin-1 prevents glutamate-induced neurotoxicity in organotypic rat brain slices.
Ferrostatin-1 (2 μM; 24 h) prevents Glutamate (5 mM)-induced neurotoxicity in a rat organotypic hippocampal slice culture (OHSC).
Ferrostatin-1 inhibits lipid peroxidation, but not mitochondrial reactive oxygen species formation or lysosomal membrane permeability.
Ferrostatin-1 inhibits cell death in cellular models of Huntington's disease (HD), periventricular leukomalacia (PVL), and kidney dysfunction.
Ferrostatin-1 (1 μM; 6 h) inhibits the oxidative destruction of unsaturated fatty acids in HT-1080 cells, thus increases the number of healthy medium spiny neurons (MSNs).
Ferroptosis-sensitive Cell Lines
| Ferroptosis-sensitive Cells |
Ferrostatin-1 Experimental Conditions |
Ferroptosis Inducers |
| HT-1080 |
0.5 μM; 24 h; EC50=60 nM |
Erastin (10 nM-100 μM; 24 h) |
| BEAS-2B |
2 μM; 16 h |
LPS (10 mg/L; 16 h) |
| PC12 (differentiated) |
1 μM; 12 h |
Erastin (7.5 μM; 12 h) |
| N27 neuron |
0.004-0.25 μM; 24 h; EC50=0.039 μM |
RSL3 (1 μM; 24 h) |
| BMSCs |
1 μM; 24 h |
GSDH (10-50 μM; 24 h) |
| HT-22 |
3-12 μM; 16 h |
Glutamate (5 mM; 16 h) |
| HK?2 |
100 μM; 24 h |
Oxalate (2 mM; 24 h) |
| MLE12 |
1 and 5 μM; 24 h |
8% and 20% cyclic stretching (CS) |
| HaCaT |
10 μM |
UVB (20mJ/cm2) |
| Mouse primary astrocytes |
0.1-2 μM; 24 h |
Angiotensin II (10 μM; 24 h) |
| SKOV3 |
5 μM; 24 h |
Erastin (10 μM; 24 h) |
| OVCA429 |
10 μM; 24 h |
Erastin (20 μM; 24 h) |
| HK-2 WT |
Pretreatment with 2 μM followed by co-treatment with inducers |
RSL3 (0.01-1 μM; 8 h) |
| MDA-MB-468 |
Pretreatment with 2 μM for 1 h was performed, followed by co-treatment with the inducer |
RSL3 (500 nM; 2 h) |
| NCI-H1299 |
Pretreatment with 2 μM followed by co-treatment with inducers |
Erastin (5 μM; 18 h) |
| HT22 neuron |
Cells were pretreated with the inducer and then co-treated with 10 and 20 μM Ferrostatin-1 for 6, 12, or 24 h |
Erastin (0 and 5 μM; 12 h) |
| HT22 neuron |
Pretreatment with 2 μM for 30 min was performed, followed by co-treatment with the inducer for 24 h |
Erastin (1 μM; 24 h) |
| HT-1080 |
0.5 μM; 12 h |
Erastin (10 μM; 12 h) |
| H1975 |
Pretreatment with 2 μM for 14 h followed by co-treatment with the inducer for 24 h |
RSL3 (1 μM; 6 or 24 h) |
| A549 |
Pretreatment with 2 μM for 14 h followed by co-treatment with the inducer for 24 h |
RSL3 (1 μM; 6 or 24 h) |
In Vivo: Ferrostatin-1 (5 mg/kg; ip; single dose, 30 min before glycerol injection) improves renal function in mice with rhabdomyolysis, whereas no beneficial effects were observed with the pan-caspase inhibitor zVAD or in RIPK3-deficient mice.
Ferrostatin-1 (0.8?mg/kg; tail vein injection) effectively alleviates LPS-induced induced acute lung injury (ALI).
Ferrostatin-1 (i.p.; 5 mg/kg; C57BL/6J mice) improves renal function in mice with rhabdomyolysis.
Ferrostatin-1 (10 mg/kg/d, i.p., 3 d) attenuates hypoxic-ischemic brain damage-, oxygen-glucose deprivation-, or Erastin (HY-15763)-induced ferroptosis in brain of neonatal rats.
Ferrostatin-1 (0.655 mg/kg, i.p., 3 times a week for 6 week) exerts anti-ferroptosis effects by increasing GPX4 activity and by inhibiting lipid peroxidation in the salivary gland of ovariectomized (postmenopausal model) rats.
相關(guān)產(chǎn)品：Bioactive Compound Library Plus | Anti-Infection Compound Library | Apoptosis Compound Library | Anti-Cancer Compound Library | Antioxidant Compound Library | Antifungal Compound Library | Ferroptosis Compound Library | Highly Selective Inhibitors Library | Cell Death Library | Radioprotector Library | Bioactive Compound Library Max | Anti-Fibrosis Compound Library | Rapamycin | Erastin | Cisplatin | Cycloheximide | RSL3 | Acetylcysteine | Staurosporine | ML385 | Sorafenib | Necrostatin-1 | Rosiglitazone | SP600125 | Hygromycin B | Liproxstatin-1 | Resveratrol | Tunicamycin | Curcumin | Oligomycin | Simvastatin | Camptothecin | Acetaminophen | L-Glutathione reduced | Hemin | Trolox | Roxadustat | NADPH tetrasodium salt | Lapatinib | Lovastatin | Filipin complex
熱門(mén)產(chǎn)品線：重組蛋白 | 藥物篩選 | 天然產(chǎn)物 | 熒光染料 | PROTAC | 同位素標(biāo)記物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介紹:
? MCE (MedChemExpress) 擁有200 多種全球獨(dú)家化合物庫(kù)，我們致力于為全球科研客戶提供前沿最全的高品質(zhì)小分子活性化合物,；
? 50,000 多種高選擇性抑制劑,、激動(dòng)劑涉及各熱門(mén)信號(hào)通路及疾病領(lǐng)域；
? 產(chǎn)品種類(lèi)涵蓋各種重組蛋白,，多肽,，常用試劑盒 ，更有 PROTAC,、ADC 等特色產(chǎn)品,，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項(xiàng)目,；
? 提供虛擬篩選,，離子通道篩選，代謝組學(xué)分析檢測(cè)分析,，藥物篩選等專(zhuān)業(yè)技術(shù)服務(wù),；
? 設(shè)有專(zhuān)業(yè)的實(shí)驗(yàn)中心和嚴(yán)格的質(zhì)控、驗(yàn)證體系,；
? 提供 LC/MS,、NMR、HPLC,、手性分析、元素分析等各項(xiàng)質(zhì)檢報(bào)告,，確保產(chǎn)品的高純度,、高品質(zhì)；
? 產(chǎn)品的生物活性多經(jīng)各國(guó)客戶實(shí)驗(yàn)驗(yàn)證,；
? Nature, Cell, Science 等多種頂級(jí)期刊及制藥專(zhuān)利收錄了MCE客戶的科研成果,；
? 專(zhuān)業(yè)團(tuán)隊(duì)跟蹤最新的制藥及生命科學(xué)研究進(jìn)展，為您提供全球最新的活性化合物,；
? 與世界各大制藥公司及知名科研機(jī)構(gòu)建立了長(zhǎng)期的合作,。
分類(lèi)糾錯(cuò)
舉報(bào)
糾錯(cuò)
收 藏
比價(jià)
算.png?x-oss-process=image/resize,h_600,w_600){kind=small}
線下結(jié)算卡.png?x-oss-process=image/resize,h_600,w_600){kind=small}
公務(wù)卡銀支付.png?x-oss-process=image/resize,h_600,w_600){kind=small}
網(wǎng)銀支付
微信
支付寶
在線客服
店內(nèi)搜索
